Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reteplase vs Standard IV Thrombolysis in Acute Ischemic Stroke
NCT05900674Phase 2Withdrawn
- Sponsor
- Zeenat Qureshi Stroke Institute
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
A Phase 2 trial of reteplase in ischemic stroke, sponsored by Zeenat Qureshi Stroke Institute. Planned start Jul 2023; status: withdrawn.
02
Drugs
reteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05900674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900674.